Charles River Laboratories vs GenScript: CDMO Comparison

How does Charles River Laboratories compare to GenScript for CAR-T manufacturing?

Side-by-side comparison of Charles River Laboratories and GenScript on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score
92/100
Quality (FDA + GMP)
99/100
FDA inspections
8
— NAI / VAI / OAI
5 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
9
MHRA GMP certificates (compliant)
2
Clinical programs (matched)
0
Capacity
Limited
Modalities
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Piscataway, NJ (US HQ); Nanjing, China (primary operations)
Signal Score
66/100
Quality (FDA + GMP)
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Modalities
CAR-T, Cell Therapy, Gene Editing

Key differences

  • Charles River Laboratories has more FDA inspections on record (8 vs 0) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Charles River Laboratories holds 9 active EMA GMP certificates; GenScript does not appear in EudraGMDP.
  • Charles River Laboratories maintains 2 MHRA / UK GMP certificates; GenScript does not.
  • Composite Signal Score: Charles River Laboratories 92/100 vs GenScript 66/100 — a 26-point gap reflecting the combined quality, capacity and financial signal.

On a 13-modality CDMO landscape, both Charles River Laboratories and GenScript qualify as CAR-T manufacturers; Charles River Laboratories carries the higher composite Signal Score for CAR-T programs in this comparison.

What to evaluate for CAR-T programs

Both Charles River Laboratories and GenScript qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Vector supply

CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.

Autologous logistics & turnaround

Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.

Closed, scalable processing

Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

See all CAR-T CDMOs ranked by Signal Score →

Frequently asked: Charles River Laboratories vs GenScript

How does Charles River Laboratories compare to GenScript for CAR-T manufacturing?

On CDMO Signal's composite Signal Score, Charles River Laboratories is 92/100 and GenScript is 66/100; Charles River Laboratories has 8 FDA inspections on record vs 0 for GenScript; European coverage is 11 active EMA+MHRA certificates for Charles River Laboratories vs 0 for GenScript. Both are tracked in the CDMO Signal directory as CAR-T CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Charles River Laboratories or GenScript?

Both Charles River Laboratories and GenScript maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Charles River Laboratories has 8 FDA inspections on record; GenScript has 0.

How do Charles River Laboratories and GenScript compare on European GMP coverage?

Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. GenScript holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for CAR-T manufacturing — Charles River Laboratories or GenScript?

Both Charles River Laboratories and GenScript are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Charles River Laboratories carries a Signal Score of 92/100 and GenScript carries 66/100 — a substantial lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Charles River Laboratories and GenScript for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.